Grant: Project Grant
University of Alberta
$1,269,900.00
Leukocyte activation via endothelin-1 as a key regulator of futile recanalization after ischemic stroke
FY 2021-22
Summary
Restoring blood flow to ischemic brain improves outcomes in patients with stroke. Although treatment with endovascular therapy (EVT) is very effective at recanalizing large cerebral vessels, over half of treated patients still have persistent major disability. Small vessels that maintain flow before and after EVT may become impaired, preventing delivery of oxygen and glucose to brain tissue. This proposal will assess the role of white blood cells in EVT treated stroke patients in contributing to poor stroke outcome. Patterns of gene expression in white blood cells from stroke patients with poor outcome even after successful EVT will be identified. We will use mouse models of stroke to study the effects of white blood cells on blood flow during and after flow in the occluded vessel is restored. Live animal imaging will permit evaluation of white blood cell activation and adhesion in relationship to blood flow cerebral microvessels and define the role of these cells in impeding flow in these vessels. Tools to deplete these cells and to genetically target activation of these cells will be used to confirm the mechanism that leads to blocked blood vessels. Strategies to modulate signalling in these cells to improve flow in microvessels and improve outcome will be examined. We aim to demonstrate how these cells are altered by stroke and contribute to microvascular failure that leads to poor outcome after stroke, and how their signalling can be targeted to improve stroke outcome.
Department
Program
Project Grant
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
450746
Name
Winship Ian R
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Systems & Circuits Neurosciences - A
Projecttitle
Leukocyte activation via endothelin-1 as a key regulator of futile recanalization after ischemic stroke
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$1,269,900
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Capillaries; Collateral Blood Flow; Endovascular Therapy; Infarct; Leukocytes; Middle Cerebral Artery Occlusion; Neutrophils; Stroke; Thrombolysis; Two Photon Microscopy
Abstract
Restoring blood flow to ischemic brain improves outcomes in patients with stroke. Although treatment with endovascular therapy (EVT) is very effective at recanalizing large cerebral vessels, over half of treated patients still have persistent major disability. Small vessels that maintain flow before and after EVT may become impaired, preventing delivery of oxygen and glucose to brain tissue. This proposal will assess the role of white blood cells in EVT treated stroke patients in contributing to poor stroke outcome. Patterns of gene expression in white blood cells from stroke patients with poor outcome even after successful EVT will be identified. We will use mouse models of stroke to study the effects of white blood cells on blood flow during and after flow in the occluded vessel is restored. Live animal imaging will permit evaluation of white blood cell activation and adhesion in relationship to blood flow cerebral microvessels and define the role of these cells in impeding flow in these vessels. Tools to deplete these cells and to genetically target activation of these cells will be used to confirm the mechanism that leads to blocked blood vessels. Strategies to modulate signalling in these cells to improve flow in microvessels and improve outcome will be examined. We aim to demonstrate how these cells are altered by stroke and contribute to microvascular failure that leads to poor outcome after stroke, and how their signalling can be targeted to improve stroke outcome.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Winship, Ian R; Jickling, Glen
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,269,900~ $0~